DNA — Ginkgo Bioworks Holdings Balance Sheet
0.000.00%
- $454.98m
- -$106.25m
- $227.04m
- 54
- 47
- 30
- 39
Annual balance sheet for Ginkgo Bioworks Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 381 | 1,550 | 1,316 | 944 | 562 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 24.2 | 150 | 84 | 31.7 | 22.4 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 427 | 1,723 | 1,450 | 1,002 | 603 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 121 | 146 | 716 | 397 | 598 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 675 | 2,071 | 2,539 | 1,665 | 1,377 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 73.2 | 135 | 173 | 164 | 107 |
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 214 | 566 | 803 | 568 | 661 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 461 | 1,505 | 1,736 | 1,097 | 716 |
Total Liabilities & Shareholders' Equity | 675 | 2,071 | 2,539 | 1,665 | 1,377 |
Total Common Shares Outstanding |